# Cyted

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cyted

- Industry: Healthcare
- Headquarters: Cambridge, UK
- Website: www.cytedhealth.com
- Latest round: Series B (Aug 1, 2025)
- Investors on record: 5

## About

Cyted Ltd, based in the UK, specializes in gastrointestinal health through a non-endoscopic diagnostic platform that enhances early detection of esophageal conditions, striving to improve patient outcomes in medical diagnostics.Founded in 2020 in Cambridge, UK, Cyted Ltd develops innovative diagnostic technologies for gastrointestinal health. The firm raised undisclosed amount of in Series B funding on August 1, 2025, co-led by new investors EQT Life Sciences, British Business Bank, and Advent Life Sciences. Returning investors Morningside Venture Partners, BGF Ventures, and individual other unspecified investors also participated in the round. This funding will support their expansion into the U.S. market, increase production capacity, and advance their diagnostic technologies.Cyted Health's core product, the EndoSign® device, utilizes a minimally invasive capsule sponge technology for comprehensive cell collection from the esophagus. This innovation facilitates early detection and monitoring of conditions such as Barrett's Esophagus and esophageal neoplasia, providing safer diagnostic alternatives to traditional endoscopic procedures. The EndoSign® aims to enhance digestive health diagnostics across various healthcare providers in markets including the United States and Europe.Cyted Health's revenue model is primarily based on partnerships with healthcare providers, focusing on the distribution of the EndoSign® diagnostic device. The firm generates revenue through direct sales to medical facilities and may include consultative services related to the implementation of their diagnostic platform, relying on the establishment of strong relationships within the healthcare sector.Cyted Ltd plans to utilize the recent Series B funding to enhance its operational footprint in the UK, increase production capacity of the EndoSign diagnostic device, and drive the company's entry into the U.S. market. The funds will also support the advancement of its diagnostic technologies and the expansion of clinical research initiatives. These growth strategies are expected to unfold as the company continues to innovate its product offerings and strengthen strategic collaborations.

## Funding rounds

- Series B, Aug 1, 2025 — EQT Life Sciences, BGF Investment Management, Advent Life Sciences, Morningside, British Business Bank

## Investors

- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series B
- BGF Investment Management (https://capitalatlas.ai/funds/bgf-investment-management) — Series B
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series B
- Morningside (https://capitalatlas.ai/funds/morningside) — Series B
- British Business Bank (https://capitalatlas.ai/funds/british-business-bank) — Series B